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of arrhythmiahas has statistical signiﬁcance, OR¼3.39, 95% CI 2.30-5.00, which
means that the clinical total effective rate of the treatment of arrhythmia mainly using
Wendan decoction was superior to the control group; in the comparison with control
group, the symptoms improved efﬁciency of the Wendan decoction in the treatment of
arrhythmiahas has statistical signiﬁcance, OR¼2.65, 95% CI 1.24-5.67, which means
that the symptoms improved efﬁciency of the treatment of arrhythmia mainly using
Wendan decoction was superior to the control group; in the comparison with control
group, the electrocardiogram improved efﬁciency of the Wendan decoction in the
treatment of arrhythmiahas also has statistical signiﬁcance, OR¼2.65, 95% CI 1.24-
5.67, which means that the electrocardiogram improved efﬁciency of the treatment of
arrhythmia mainly using Wendan decoction was superior to the control group. The
funnel plot point out that there may be publication bias. The results of sensitivity
analysis are the same as the original. The results analyzed by Meta-analysis were
stable and reliable.
Conclusions: Wendan decoction is effective to treat arrhythmia,improve the
clinical symptoms and electrocardiogram of arrhythmia. But because the quality
and quantity of the research are limited, further conﬁrmation with clinical ran-
domized controlled trials of high quality, large sample and long-term follow-up are
needed.
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Effects of Inhaled iloprost on gas exchange and hemodynamics in patients with
pulmonary hypertension due to lung diseases
Wang Lan, Bai Lei, He Jing, Zhao Qinhua, Liu Jinming
Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji
University, School of Medicine, Shanghai, China
Objectives: To investigate the acute effects of inhaled iloprost on V/Q matching, and
hemodynamics in patients with pulmonary hypertension (PH) due to chronic lung
diseases.
Methods: Sixty-nine patients with chronic lung diseases and PH were diagnosed by
right heart catheterization (RHC).All patients received a single dose of 20mg iloprost
during the process of RHC, Cardiopulmonary data included hemodynamic parameters
and PaO2, PaCO2, SaO2, P(A-a) O2, venous admixture/shunt fraction (Qs$/Qt) were
measured or calculated at baseline, and 20 minutes after inhalation iloprost
respectively.
Results: nhalated iloprost caused a decrease in mPAP from 44.510.5mmHg to
41.611.4mmHg, and PVR from 7.63.6 Wood Units to 6.63.9 Wood Units
(meanSD, P<0.001, respectively), cardiac index increase from 3.20.8 L/min/m2 to
3.51.0L/min/m2 (meanSD, P<0.001). Arterial blood gas and calculated Qs$/Qt$
were maintained after iloprost. No adverse effects on systemic blood pressure were
seen.
Conclusions: Iloprost inhalation was safe in patients with PH due to lung diseases,
and improved hemodynamics but didn’t affect V/Q matching and gas change.
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Objectives: To compare the change of cardiac output(CO) during loading dose were
injecting between dexmedetomidine and propofol in patients after major abdominal
surgery.
Methods: 74 patients after major abdominal surgery were enrolled. They were
randomly divided into two groups: Dexmedetomidine group (DEX group) or Propofol
group (PRO group), 37 cases in each group. Depth of sedation was monitored using
the bispectral index (BIS), CO and other cardiodynamic date were recorded through
“Vigileo” and cardiogram monitor. When the patients could be roused, a loading
dose of fentanyl was injected at 0.0007mg/kg, followed by continuous infusion at
0.3mg/kg/h for additional analgesia. DEX group received 1 mg/kg loading dose fol-
lowed by continuous infusion of 0.3mg/kg/h. PRO group received 0.5mg/kg loading
dose followed by continuous infusion at 0.5mg/kg/h. Dose were adjusted to accom-
plish BIS value 70-80. BIS value, HR (Heart rate), SV (stroke volume) and CO were
recorded at 0min, 5min, 10min, 30min.
Results: Both groups were able to achieve the target sedation level according to BIS
value. There were no differences in BIS values between DEX group and PRO group
(61.2312.73 vs 62.5513.67 P¼0.127). After the loading dose, DEX group caused
HR decrease signiﬁcantly than PRO group [P¼0.006]. SV showed different effect in
both groups, SV augmented signiﬁcantly in DEX group after the loading dose, as SV
decreased signiﬁcantly in PRO group. SV were signiﬁcantly decreased in PRO groups
than DEX groups (6423 vs 9029ml, P¼0.008) in the ﬁfth minutes. HR decreased
signiﬁcantly in DEX group during the loading dose period, HR decreased slightly in
PRO group, HR were signiﬁcant different between the two groups (7214 vs
8415bpm, P¼0.006). CO declined signiﬁcantly in groups comparing to the level
before the sedation (PDex<0.001, PPro<0.001). CO were signiﬁcantly decreased in
PRO groups than DEX groups in the ﬁfth minutes (5.41.7 vs 6.42.0 L/min,
P<0.05).JACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CConclusions: Propofol can signiﬁcant decrease cardiac output than dexmedetomidine
during the loading time in the patients after major abdominal surgery. So monitoring
the cardiodynamics changes carefully during sedation are required.
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Effect of different dose of Statins on the Antiplatelet Potency of Clopidogrel in
Patients with Acute Myocardial Infarction
Tan Gangwen1, Wu tongguo1
1Guangzhou Red Cross Hospital, 2Jinan University
Objectives: Comparison of the inﬂuence on the platelet aggregation of clopidogrel
combined with different metabolic pathways statins in patients with acute myocardial
infarction.
Methods: From May 2013 to November 2013, there were 80 patients with acute
myocardial infarction treated with emergency PCI enrolled into this study. They were
randomly divided into the atorvastatin group (group A 40 cases); rosuvastatin group
(group B 40 cases). All patients chewed Aspirin 300mg and received clopidogrel
300mg before emergency PCI. Patients in group A received atorvastatin 80mg, Group
B received rosuvastatin 40mg before emergency PCI. Patients in group A received
atorvastatin 40mg/qd and patients in group B received rosuvastatin 20mg/qd after PCI.
All patients received dual antiplatelet therapy with aspirin 100mg/qd and clopidogrel
75mg/qd.Statins and clopidogrel were given before breakfast. The platelet aggregation
rate was measured with whole blood impedance aggregometry on the 7 days and 30
days. We observed the major adverse cardiovascular events (MACE): cardiac death,
recurrent angina, recurrent myocardial infarction, target vessel revascularization and
deterioration of cardiac function in patients after 30 days. We compared the difference
of platelet aggregation and MACE rate between the two groups. Testing the alanine
aminotransferase, creatinine, total cholesterol and low-density lipoprotein in the ﬁrst
24 hours and 30 days after PCI and recording the quantity of patients who had muscle
pain , headache, and so on after 30 days to evaluate the effects of lipid-lowering and
drug safety.
Results: (1).After PCI, on the 7th day and 30th day, we compared the platelet ag-
gregation of group A with group B. The result were (3.093.99 vs 3.794.20
P¼0.45) and (2.593.48 vs 2.994.20 P¼0.6). The platelet aggregation of group B
was slightly higher than group A in the both time but no statistical difference. (2) After
30 days, there were 9 patients (22.5%) with recurrent angina, 3 patients (7.5%) with
deterioration of heart function in group A and 5 patients (12.5%) with recurrent
angina, 4 patients (10 %) with deterioration of heart function in group B. There was no
signiﬁcant difference between the two groups of patients in adverse events and overall
MACE (P> 0.05). (3) After 30 days the level of patients’ TC and LDL-C was
decreased signiﬁcantly (P<0.05). According to the level of LDL-C <1.8mmol / l or
LDL-C decreased by 50% compared to the admission, we compared the percentage of
patients who’s level of LDL-C reached the goal in the two groups (55% vs 62.5%
P¼0.49). (4) The level of patients’ ALT and Cr were no signiﬁcant difference
compared to the admission (P>0.05). There was one patients (2.5%) with
ALT>3ULN in group A and 0 in group B. There was no patient with CK>5ULN.
Conclusions: The effect of different dose of statins on the antiplatelet potency of
clopidogrel inpatients with acute myocardial infarction was similar.
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Objectives: Nesiritide is prescribed to the patients with acute decompensate heart
failure (ADHF) with dyspnea according to 2012 European Society of Cardiology
(ESC) guidelines. However, a few randomized, controlled trials (RCTs) were carried
out in recent years and there has been conﬂicting reports on the effects of Nesiritide to
improve the rate of mortality and rehospitalization. Therefore, we conducted a meta-
analysis with the addition of new RCTs to produce a more reliable conclusion about
the beneﬁts received from the short- and long-term Nesiritide therapy in adults with
ADHF. Additionally, a cumulative meta-analysis on how evidence for Nesiritide has
evolved in the treatment of ADHF was performed.
Methods: To identify RCTs that evaluated the mortality and adverse events on adults
with ADHF after Nesiritide therapy, extensive searches were carried out within
MEDLINE, EMBASE, CINAHL, SIGLE, Web of Science and the Cochrane Central
Register of Controlled Trials (through August 10, 2013). When necessary, searches of
bibliographies using Medical Subject Heading terms and a standardized protocol were
also performed. Two independent reviewers identiﬁed trials, extracted data, and
assessed risk of bias.
Results: A total of 10213 patients with ADHF in ﬁfteen trials were included and
divided into the Nesiritide group (Nesiritide plus conventional treatment) and theardiovascular Disease Clinical Research C205
control groups (placebo, Nitroglycerin or Dobutamine plus conventional treatment).
The comprehensive evaluation of relative risk for 30- (RR 1.004, 95% CI 0.995-
1.014) and 180-day (RR 1.006, 95% CI 0.988-1.024) mortality showed no signiﬁcant
differences between two groups. There was no signiﬁcant difference in the mortality
rate between the group of less than 30-day (RR 1.015, 95% CI 0.989-1.041) and the
group of 90-day (RR 1.011, 95% CI 0.974-1.048). Moreover, there was also no
signiﬁcant difference found between the 30- (RR 1.011, 95% CI 0.998-1.024) and 90-
day readmission rate (RR 1.049, 95% CI 0.963-1.144). In the meantime, cumulative
meta-analysis demonstrated no statistically signiﬁcant beneﬁts on improving the
mortality rate with Nesiritide administration in ADHF.
Conclusions: Neither mortality nor readmission to the hospital was reduced or
increased for any length of follow-up after treatment with Nesiritide in addition to
conventional treatment in adult patients with ADHF. Further investigation on the
mortality beneﬁt of Nesiritide treatment in patients with ADHF is unlikely to yield a
positive result. Although Nesiritide could reduce dyspnea to some extent if added to
conventional treatment, strict attention should be paid on the pharmaceutical indica-
tion for patient with ADHF.
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Effects of Ginkgo biloba extract in combination with anti-platelet drugs on
platelet aggregation: a meta-analysis of randomized controlled trials
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Objectives: The effects of Ginkgo biloba extract (GBE) in combination with anti-
platelet drugs on platelet aggregation were not clear. The objective of this meta-
analysis is to elucidate the effects of GBE in combination with anti-platelet drugs on
platelet aggregation and bleeding time in order to provide reference proof for rational
use of them.
Methods: Randomized controlled trails (RCTs) were searched from PubMed, Spring
Ling, Biosis Previews and The Cochrane without restriction of year and language.
RCTs involving the combination of GBE with anti-platelet drugs and assessing the
effects of the combination on platelet aggregation or bleeding time were included.
Collagen-induced platelet aggregation, ADP-induced platelet aggregation and
bleeding time were used as analysis indexes. A meta-analysis was performed by
RevMan 5.0.
Results: Six RCTs with 316 participants were included in the meta-analysis. The
combination of GBE with anti-platelet drugs has inhibitory trend on ADP-induced
platelet aggregation [MD¼-3.45, 95% CI (-7.39, 0.50), P¼0.09], and no inhibitory
effect on collagen-induced platelet aggregation [MD¼-0.56, 95% CI (-3.91, 2.80),
P¼0.74]. No difference of prolonged bleeding time between the combination and anti-
platelet drugs used alone was noted [MD¼0.39, 95% CI (-0.09, 0.86), P¼0.11].
Conclusions: The meta-analysis suggested that compared with anti-platelet drugs
used alone, the combination of GBE with anti-platelet drugs here may not be sig-
niﬁcant inhibition on platelet aggregation, but in view to fewer studies included, the
conclusion is prudent to be applied to clinical practice and need. Larger scale
multicenter randomized controlled trial to validate in the future.
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Objectives: Elevated serum inﬂammatory markers, such as high sensitivity C-reactive
protein (hs-CRP), were regarded as risk factors for cardiovascular events. Sodium
tanshinone IIA sulfate (STS), an extract of the root of Salvia miltiorrhiza, has been
proved to have anti-inﬂammatory effects in basic researches, but the evidence sup-
porting such efﬁcacy in Coronary Heart Disease (CHD) patients remains unclear. The
purpose of this study was to access the effects of STS on elevated serum hs-CRP and
other inﬂammatory markers in patients with CHD.
Methods: This is a prospective randomized open-label blinded end point (PROBE)
designed trial. The study protocol has been approved by Ethics Committee of Xiyuan
Hospital, China Academy of Chinese Medical Sciences (2012XL022-2). 72 conﬁrmed
CHD inpatient of unstable angina (UA) or acute non-ST segment elevation myocardial
infarction (NSTEMI) with elevated serum hs-CRP were enrolled and randomized 1:1
into the control or experimental group. The control group received standard medi-
cation for treatment of CHD including 20mg atorvastatin while the experimental
group additionlly received intravenously a daily 80mg dose of STS for 14 days. The
primary outcome was serum Hs-CRP level. The secondary outcomes were other
serum imﬂammatory factors and improvement in symptoms of angina as well as side
effects. Outcome parameters were assessed blindly to treatment allocation at baseline,
immediately after the 14-day treatment period and at 30 days after the treatment
stopped.
Results: After 14-day treatment, the level of hs-CRP were signiﬁcantly reduced
(6.363.42 mg/l to 2.835.94 mg/l and 5.752.39 mg/l to 1.024.31 mg/l) in both
the experimental and control groups; The reduction of the experiment group was moreC206 JACC Vol 64/16/Suppl C j October 16–1signiﬁcant than that of the control group (P¼0.0485, IQR: 2.9(1.3, 6.05) vs 1.54
(-1.45, 3.51) mg/dL), so as the pecent change (P¼0.0114, media: 71.75% vs 30%).
The reduction in monocyte chemotactic protein 1 (MCP-1) and soluble CD40 ligand
(sCD40L) of the experiment group was more signiﬁcant than that of the control group
(P¼0.013 and P¼0.0454, respectively). At 30 days after the treatment stopped, the
level of MCP-1 had greater reduction in the experiment group compared with that of
the control group (P¼0.0253, 54.6447.38 vs 30.7239.82 pg/dL). Other inﬂam-
matory markers had no signiﬁcant reduction between groups. In addition, STS also
signiﬁcantly improved angina symptom at the two time-points after treatment. There
were no serious adverse events occurred.
Conclusions: On the background of statin therapy, a daily 80mg dose of STS intra-
venously for 14 days further reduced levels of circulating inﬂammatory markers of hs-
CRP, sCD40L and MCP-1 in UA/NSTEMI patients. Together, our study suggested
that STS could be used as a complementary treatment in CHD patients with enhanced
inﬂammatory reaction.
(Clinical Trial Registration number: ChiCTR-TRC-12002361).
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Beneﬁcial effect of Qishen Capsule on serum resistin levels in unstable angina
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Objectives: Resistin is a novel adipokine that is involved in inﬂammatory conditions
and atherosclerosis. In this study we aimed to investigate the beneﬁcial effect of
Qishen Capsule on serum resistin levels in unstable angina.
Methods: 154 unstable angina patients were randomly assigned to two groups. One
group (regular group) received oral aspirin, clopidogrel, beta-blockers, and heparin;
the other group (combined group) received regular treatment and Qishen Capsule
(three pills, third per day). Study drugs were administered for six weeks in both
groups. Resistin levels were measured using ELISA at the beginning of the study and
at study end. Patients were evaluated monthly for blood pressure, fasting serum
glucose levels and adverse events.
Results: Both therapeutic regimens reduced resistin levels; combined treatment group
resulted in a greater decrease in resistin levels (4.171.52 ng/mL to 2.050.92 ng/
mL) when compared with regular treatment group (3.951.46 ng/mL to 2.390.91
ng/mL) (P<0.05). None of the patients experienced adverse events.
Conclusions: Results showed that combined treatment group resulted in a greater
reduction in resistin levels than regular treatment group alone.
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The effects and safety between high-dose Atorvastatin and Rosuvastatin in Acute
myocardial infarction patients
Zhang Wenduo, Wang Fang
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Objectives: To nvestigate whether it is the same by application of rosuvastatin 20mg
as atorvastatin 40mg on effectiveness and safety in patients with acute myocardial
infarction (AMI).
Methods: A total of 130 AMI patients enrolled in the study, all patients underwent
standardized treatment as guidelines recommend. After admission they were seperated
into two groups: atorvastatin 40mg/day group and and rosuvastatin 20mg/day group,
and wiould continue to take the medicine for 30 days. The primary end point was the
reduction of serum LDL-c levels, all-cause mortality, re-AMI, readmission rate within
30 days. Secondary endpoint were serum transaminases, bilirubin, serum creatinine,
urine protein.
Results: There was no signiﬁcant difference between the two groups (0.321.36,
0.401.13, P¼0.737) about the reduction of serum LDL-c levels and primary clinical
endpoint of all-cause mortality (P¼0.699), the incidence of re-AMI, readmission rate
within 30 days was lower in rosuvastatin group than in atorvastatin group (P¼0.005,
0.018, respectively). There is no no signiﬁcant difference on alanine aminotransferase
and total bilirubin between the two groups. However, the urinary protein levels
increased more in rosuvastatin group than in atorvastatin group (0.100.03 vs
0.170.05, P¼0.009), while serum creatinine levels had the same trend (80.329.6 vs
101.766.9, P¼0.030). After multivariate analysis, it is not statin used but BNP
levels, which was independent risk factors affect the prognosis.
Conclusions: Compared with atorvastatin 40mg/day, rosuvastatin 20mg/day can
reduced re-AMI, readmission rate within 30 days. However, it increased urinary
protein levels and elevated serum creatinine levels. So overall all-cause death,
myocardial infarction again, readmission rates did not differ between the two groups.
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Analysis of Anticoagulation Therapy in Very Elderly Patients with Nonvalvular
Atrial Fibrillation
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Objectives: To investigate the current status of thromboembolism risk and antith-
rombotic treatment in very elderly patients(age80) with nonvalvular atrial9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
